104 related articles for article (PubMed ID: 19502103)
1. Presurgical serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in oral squamous cell carcinoma.
Liu CJ; Chang KW; Lin SC; Cheng HW
Oral Oncol; 2009 Oct; 45(10):920-5. PubMed ID: 19502103
[TBL] [Abstract][Full Text] [Related]
2. Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma.
Shang ZJ; Li JR; Li ZB
Int J Oral Maxillofac Surg; 2002 Oct; 31(5):495-8. PubMed ID: 12418564
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC).
Laack E; Scheffler A; Burkholder I; Boeters I; Andritzky B; Schuch G; Görn M; Vohwinkel G; Edler L; Fiedler W; Hossfeld DK
Lung Cancer; 2005 Oct; 50(1):51-8. PubMed ID: 15992959
[TBL] [Abstract][Full Text] [Related]
4. [Expression and clinical significance of matrix metalloproteinase-9 and vascular endothelial growth factor in oral squamous cell carcinomas].
Xu H; Shi XP; Tang WP; Li LX
Ai Zheng; 2002 Sep; 21(9):983-8. PubMed ID: 12508547
[TBL] [Abstract][Full Text] [Related]
5. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.
Tamura M; Oda M; Matsumoto I; Tsunezuka Y; Kawakami K; Ohta Y; Watanabe G
Ann Surg Oncol; 2004 Oct; 11(10):928-33. PubMed ID: 15383417
[TBL] [Abstract][Full Text] [Related]
6. Expression of vascular endothelial growth factor-C does not predict occult lymph-node metastasis in early oral squamous cell carcinoma.
Faustino SE; Oliveira DT; Nonogaki S; Landman G; Carvalho AL; Kowalski LP
Int J Oral Maxillofac Surg; 2008 Apr; 37(4):372-8. PubMed ID: 18295452
[TBL] [Abstract][Full Text] [Related]
7. Cyclo-oxygenase-2 expression is associated with vascular endothelial growth factor C expression and lymph node metastasis in oral squamous cell carcinoma.
Kono M; Watanabe M; Abukawa H; Hasegawa O; Satomi T; Chikazu D
J Oral Maxillofac Surg; 2013 Oct; 71(10):1694-702. PubMed ID: 23809761
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer.
Laack E; Köhler A; Kugler C; Dierlamm T; Knuffmann C; Vohwinkel G; Niestroy A; Dahlmann N; Peters A; Berger J; Fiedler W; Hossfeld DK
Ann Oncol; 2002 Oct; 13(10):1550-7. PubMed ID: 12377642
[TBL] [Abstract][Full Text] [Related]
9. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the clinical significance of serum vascular endothelial growth factor and matrix metalloproteinase-9 in patients with hepatocellular carcinoma.
Kamel L; Nessim I; Abd-el-Hady A; Ghali A; Ismail A
J Egypt Soc Parasitol; 2005 Dec; 35(3):875-90. PubMed ID: 16333896
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathologic features and prognostic factors of cervical lymph node metastasis in oral squamous cell carcinoma].
Li XM; DI B; Shang YD; Li J; Cheng JM
Ai Zheng; 2005 Feb; 24(2):208-12. PubMed ID: 15694035
[TBL] [Abstract][Full Text] [Related]
12. Expression of c-erbB receptors, MMPs and VEGF in squamous cell carcinoma of the head and neck.
Do NY; Lim SC; Im TS
Oncol Rep; 2004 Aug; 12(2):229-37. PubMed ID: 15254682
[TBL] [Abstract][Full Text] [Related]
13. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
[TBL] [Abstract][Full Text] [Related]
14. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma.
de Vicente JC; Fresno MF; Villalain L; Vega JA; Hernández Vallejo G
Oral Oncol; 2005 Mar; 41(3):283-93. PubMed ID: 15743691
[TBL] [Abstract][Full Text] [Related]
15. Prediction of outcome of patients with oral squamous cell carcinoma using vascular invasion and the strongly positive expression of vascular endothelial growth factors.
Seki S; Fujiwara M; Matsuura M; Fujita S; Ikeda H; Asahina I; Ikeda T
Oral Oncol; 2011 Jul; 47(7):588-93. PubMed ID: 21602095
[TBL] [Abstract][Full Text] [Related]
16. [Effect of the levels of vascular endothelial growth factor-A and C on the prognosis of patients with laryngeal carcinoma].
Düzen B; Taş A; Demir M; Usta U; Yağız R; Koten M; Karasalihoğlu A
Kulak Burun Bogaz Ihtis Derg; 2011; 21(3):122-8. PubMed ID: 21595615
[TBL] [Abstract][Full Text] [Related]
17. Expression of cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2 in patients with primary laryngeal carcinoma: a tissue microarray study.
Dong P; Li X; Yu Z; Lu G
J Laryngol Otol; 2007 Dec; 121(12):1177-83. PubMed ID: 17888194
[TBL] [Abstract][Full Text] [Related]
18. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.
Iwasaki A; Kuwahara M; Yoshinaga Y; Shirakusa T
Eur J Cardiothorac Surg; 2004 Mar; 25(3):443-8. PubMed ID: 15019676
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma.
Riedel F; Götte K; Schwalb J; Hörmann K
Anticancer Res; 2000; 20(5A):3045-9. PubMed ID: 11062721
[TBL] [Abstract][Full Text] [Related]
20. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker.
Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
Int J Cancer; 2005 Sep; 116(3):422-7. PubMed ID: 15818624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
